Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more
Pasithea Therapeutics Corp (KTTA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.237x
Based on the latest financial reports, Pasithea Therapeutics Corp (KTTA) has a cash flow conversion efficiency ratio of -0.237x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($12.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pasithea Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Pasithea Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pasithea Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pasithea Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Indbank Merchant Banking Services Limited
NSE:INDBANK
|
-0.033x |
|
ARCONTECH GROUP LS-125
F:KTSA
|
N/A |
|
Pacific Oil Co
PINK:FGCO
|
0.099x |
|
Sical Logistics Limited
NSE:SICALLOG
|
N/A |
|
Lena Lighting S.A.
WAR:LEN
|
0.016x |
|
Vichitbhan Palmoil Public Company Limited
BK:VPO
|
0.229x |
|
Intrasoft Technologies Limited
NSE:ISFT
|
0.042x |
|
Hexagon Resources Ltd
AU:HXG
|
-0.766x |
Annual Cash Flow Conversion Efficiency for Pasithea Therapeutics Corp (2020–2024)
The table below shows the annual cash flow conversion efficiency of Pasithea Therapeutics Corp from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.78 Million | $-13.92 Million | -0.942x | -64.15% |
| 2023-12-31 | $23.40 Million | $-13.43 Million | -0.574x | -78.10% |
| 2022-12-31 | $42.50 Million | $-13.69 Million | -0.322x | -421.90% |
| 2021-12-31 | $51.42 Million | $-3.17 Million | -0.062x | +61.49% |
| 2020-12-31 | $241.35K | $-38.69K | -0.160x | -- |